Pathophysiology of hepatitis C and HIV coinfection

Journal of the Association of Nurses in AIDS Care

Volumn 14, Issue 5 SUPPL., 2003, Pages 27S-51S

  Phillips, Kenneth D ^a   Brewer, Robyn ^a  

^a UNIVERSITY OF SOUTH CAROLINA   (United States)

Author keywords

Alpha interferon; Diagnosis; Hepatitis C; HIV; Pathogenesis; Pathophysiology; Pharmacotherapy; Ribavirin; Treatment

Indexed keywords

ALCOHOL; ALDEHYDE; ALPHA INTERFERON; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIHISTAMINIC AGENT; ANTIVIRUS AGENT; BENZODIAZEPINE DERIVATIVE; CYANOCOBALAMIN; DIDANOSINE; FOLIC ACID; HEPATITIS B VACCINE; IMMUNOGLOBULIN M; METHADONE; PEGINTERFERON ALPHA2B; PROTEINASE INHIBITOR; RIBAVIRIN; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZIDOVUDINE;

ALCOHOL METABOLISM; BILIRUBIN METABOLISM; BLOOD CLOTTING; BLOOD FILTRATION; BLOOD TRANSFUSION; CARBOHYDRATE DIET; CARBOHYDRATE METABOLISM; CARDIOVASCULAR DISEASE; CELLULAR IMMUNITY; CHILL; CHRONIC HEPATITIS; CONTINUING EDUCATION; DELTA AGENT HEPATITIS; DEPRESSION; DETOXIFICATION; DIET THERAPY; DISEASE TRANSMISSION; DRUG METABOLISM; FEVER; FLU LIKE SYNDROME; FOOD DRUG INTERACTION; HEADACHE; HEALTH CARE PERSONNEL; HEALTH PROMOTION; HEMODIALYSIS; HEPATIC ENCEPHALOPATHY; HEPATITIS A; HEPATITIS B; HEPATITIS C; HEPATITIS C VIRUS; HEPATITIS E; HEPATITIS G; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; HYPERLACTATEMIA; INTRAVENOUS DRUG ABUSE; LACTIC ACIDOSIS; LEUKOPENIA; LIPID METABOLISM; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FAILURE; LIVER FUNCTION; LIVER FUNCTION TEST; LUNG DISEASE; MALAISE; MORBIDITY; NURSING; OCCUPATIONAL EXPOSURE; PANCREAS DISEASE; PANCREATITIS; PATHOPHYSIOLOGY; POSTTRANSFUSION HEPATITIS; PROTEIN METABOLISM; REVIEW; SEXUALLY TRANSMITTED DISEASE; SUICIDE ATTEMPT; SUPERINFECTION; THROMBOCYTOPENIA; TREATMENT OUTCOME; VIRUS CARCINOGENESIS; VIRUS DIAGNOSIS; VIRUS TRANSMISSION; LIVER; METABOLISM; VIRUS HEPATITIS;

HEPATITIS C, CHRONIC; HEPATITIS, VIRAL, HUMAN; HIV INFECTIONS; HUMANS; LIVER; LIVER FUNCTION TESTS;

EID: 2142816480     PISSN: 10553290     EISSN: None     Source Type: Journal    
DOI: 10.1177/1055329003254855     Document Type: Article

References (128)

1. Alter, H. J., Holland, P. V., Purcell, R. H., Lander, J. J., Feinstone, S. M., Morrow, A. G., et al. (1972). Posttransfusion hepatitis after exclusion of commercial and hepatitis-B antigen-positive donors. Annals of Internal Medicine, 77, 691-699.
2. Alter, H. J., Nakatsuji, Y., Melpolder, J., Wages, J., Wesley, R., Shih, J. W., et al. (1997). The incidence of transfusion-associated hepatitis G virus infection and its relation to liver disease. New England Journal of Medicine, 336, 747-754.
3. Alter, M. J., Coleman, P. J., Alexander, W. J., Kramer, E., Miller, J. K., Mandel, E., et al. (1989). Importance of heterosexual activity in the transmission of hepatitis B and non-A, non-B hepatitis. Journal of the American Medical Association, 262, 1201-1205.
4. Alter, M. J., Kruszon-Moran, D., Nainan, O. V., McQuillan, G. M., Gao, F., Moyer, L. A., et al. (1999). The prevalence of hepatitis C virus infection in the United States, 1988 through 1994. New England Journal of Medicine, 341, 556-562.
5. Baffis, V., Shrier, I., Sherker, A. H., & Szilagyi, A. (1999). Use of interferon for prevention of hepatocellular carcinoma in cirrhotic patients with hepatitis B or hepatitis C virus infection. Annals of Internal Medicine, 131(9), 696-701.
6. Bandi, J. C., Garcia-Pagan, J. C., Escorsell, A., Francois, E., Moitinho, E., Rodes, J., et al. (1998). Effects of propranolol on the hepatic hemodynamic response to physical exercise in patients with cirrhosis. Hepatology, 28, 677-682.
7. Barkhuizen, A., Rosen, H. R., Wolf, S., Flora, K., Benner, K., & Bennett, R. M. (1999). Musculoskeletal pain and fatigue are associated with chronic hepatitis C: A report of 239 hepatology clinic patients. American Journal of Gastroenterology, 94, 1355-1360.
8. Bell, A., Neube, F., Hansell, A., Davison, K. L., Young, Y., Gilson, R., et al. (2001). An outbreak of hepatitis A among young men associated with having sex in public venues. Communicable Disease and Public Health, 4, 163-170.
9. Benhamou, Y., Bochet, M., Di Martino, V., Charlotte, F., Azria, F., Coutellier, A., et al. (1999). Liver fibrosis progression in human immunodeficiency virus and hepatitis C virus coinfected patients. The Multivirc Group. Hepatology, 30, 1054-1058.
10. Benhamou, Y., Di Martino, V., Bochet, M., Colombet, G., Thibault, V., Liou, A., et al. (2001). Factors affecting liver fibrosis in human immunodeficiency virus-and hepatitis C virus-coinfected patients: Impact of protease inhibitor therapy. Hepatology, 34(2), 283-287.
11. Berenguer, M., & Wright, T. L. (1999). Treatment strategies for recurrent hepatitis C after liver transplantation. Clinics in Liver Disease, 3, 883-899.
12. Bernuau, J., & Behamou, N. (1999). Fulminant and subfulminant liver failure. In J. Bircher, N. Benhamou, N. McIntyre, M. Rizzetto, & J. Rodes (Eds.), Oxford textbook of clinical hepatology (pp. 1341-1372). Oxford, UK: Oxford University Press.
13. Bertoletti, A., & Maini, M. K. (2000). Protection or damage: A dual role for the virus-specific cytotoxic T lymphocyte response in hepatitis B and C infection? Current Opinion in Microbiology, 3, 387-392.
14. Bizollon, T., Ducerf, C., Trepo, C., & Mutimer, D. (1999). Hepatitis C virus recurrence after liver transplantation. Gut, 44, 575-578.
15. Bruno, S., Silini, E., Crosignani, A., Borzio, F., Leandro, G., Bono, F., et al. (1997). Hepatitis C virus genotypes and risk of hepatocellular carcinoma in cirrhosis: A prospective study. Hepatology, 25, 754-758.
16. Centers for Disease Control and Prevention. (2002). National Institutes of Health Consensus Development Conference Statement: Management of Hepatitis C. Retrieved June 10-12, 2002, from http://consensus.nih.gov/cons/116/Hepc091202. pdf
17. Centers for Disease Control and Prevention. (2003). Hepatitis C: Fact sheet. Retrieved from http://www.cdc.gov/ncidod/diseases/hepatitis/c/fact.htm
18. Cerny, A., & Chisari, F. V. (1999). Pathogenesis of chronic hepatitis C: Immunological features of hepatic injury and viral persistence. Hepatology, 30, 595-601.
19. Chisari, F. V. (1997). Cytotoxic T cells and viral hepatitis. Journal of Clinical Investigation, 99, 1472-1477.
20. Choo, Q. L., Kuo, G., Weiner, A. J., Overby, L. R., Bradley, D. W., & Houghton, M. (1989). Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral hepatitis genome. Science, 244, 359-362.
21. Ciocca, M. (2000). Clinical course and consequences of hepatitis A. Vaccine, 18, S71-S74.
22. Cohen, A. (1995). Liver disease. In L. C. Copstead (Ed.), Perspectives on pathophysiology (pp. 758-775). Philadelphia: W. B. Saunders.
23. Cotler, S. J., & Jensen, D. M. (2001). Treatment of hepatitis C virus and HIV coinfections. Clinics in Liver Disease, 5, 1045-1061.
24. Crawford, J. M. (1997). The liver and biliary tract. In V. Kumar, R. S. Cotran, & S. L. Robbins (Eds.), Basic pathology (pp. 516-555). Philadelphia: W. B. Saunders.
25. Cribier, B., Schmitt, C., Rey, D., Uhl, G., Lang, J. M., Vetter, D., et al. (1997). HIV increases hepatitis C viraemia irrespective of the hepatitis C virus genotype. Research in Virology, 148, 267-271.
26. Cuthbert, J. A. (2001). Hepatitis A: Old and new. Clinical Microbiology Reviews, 14, 38-58.
27. Dienstag, J. L. (1999). Hepatitis A. In J. Bircher, N. Behamou, N. McIntyre, M. Rizzetto, & J. Rodes (Eds.), Oxford textbook of clinical hepatology (pp. 870-875). Oxford, UK: Oxford University Press.
28. Donahue, J. G., Munoz, A., Ness, P. M., Brown, D. E., Jr., Yawn, D. H., McAllister, H. A., Jr., et al. (1992). The declining risk of post-transfusion hepatitis C virus infection. New England Journal of Medicine, 327, 369-373.
29. Dumot, J. A., Barnes, D. S., Younossi, Z., Gordon, S. M., Avery, R. K., Domen, R. E., et al. (1999). Immunogenicity of hepatitis A vaccine in decompensated liver disease. American Journal of Gastroenterology, 94, 1601-1604.
30. EASL International Consensus Conference on Hepatitis C. (1999). Consensus statement. Journal of Hepatology, 30, 961.
31. Eyster, M. E., Diamondstone, L. S., Lien, J. M., Ehmann, W. C., Quan, S., & Goedert, J. J. (1993). Natural history of hepatitis C virus infection in multitransfused hemophiliacs: Effect of coinfection with human immunodeficiency virus. The Multicenter Hemophilia Cohort Study. Journal of Acquired Immune Deficiency Syndromes, 6, 602-610.
32. Eyster, M. E., Fried, M. W., Di Bisceglie, A. M., & Goedert, J. J. (1994). Increasing hepatitis C virus RNA levels in hemophiliacs: Relationship to human immunodeficiency virus infection and liver disease. Multicenter Hemophilia Cohort Study. Blood, 84, 1020-1023.
33. Farci, P., Mandas, A., Coiana, A., Lai, M. E., Desmet, V., Van Eyken, P., et al. (1994). Treatment of chronic hepatitis D with interferon alfa-2a. New England Journal of Medicine, 330, 88-94.
34. Fattovich, G., Giustina, G., Degos, F., Diodati, G., Tremolada, F., Nevens, F., et al. (1997). Effectiveness of interferon alfa on incidence of hepatocellular carcinoma and decompensation in cirrhosis type C. European Concerted Action on Viral Hepatitis (EUROHEP). Journal of Hepatology, 27, 201-205.
35. Feinstone, S. M., Kapikian, A. Z., Purcell, R. H., Alter, H. J., & Holland, P. V. (1975). Transfusion-associated hepatitis not due to viral hepatitis type A or B. New England Journal of Medicine, 292, 767-770.
36. Feitelson, M. A. (2002). Hepatitis C virus from laboratory to clinic. Cambridge, UK: Cambridge University Press.
37. Feray, C., Samuel, D., Gigou, M., Paradis, V., David, M. F., Lemonnier, C., et al. (1995). An open trial of interferon alfa recombinant for hepatitis C after liver transplantation: Antiviral effects and risk of rejection. Hepatology, 22, 1084-1089.
38. Fried, M. W. (2002). Side effects of therapy of hepatitis C and their management. Hepatology, 36, S237-S244.
39. Fried, M. W., Shiffman, M. L., Reddy, K. R., Smith, C., Marinos, G., Goncales, F. L., Jr., et al. (2002). Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. New England Journal of Medicine, 347(13), 975-982.
40. Garcia-Samaniego, J., Soriano, V., Castilla, J., Bravo, R., Moreno, A., Carbo, J., et al. (1997). Influence of hepatitis C virus genotypes and HIV infection on histological severity of chronic hepatitis C. The Hepatitis/HIV Spanish Study Group. American Journal of Gastroenterology, 92, 1130-1134.
41. Garfein, R. S., Vlahov, D., Galai, N., Doherty, M. C., & Nelson, K. E. (1996). Viral infections in short-term injection drug users: The prevalence of the hepatitis C, hepatitis B, human immunodeficiency, and human T-lymphotropic viruses. American Journal of Public Health, 86, 655-661.
42. Gaudin, J. L., Faure, P., Godinot, H., Gerard, F., & Trepo, C. (1995). The French experience of treatment of chronic type D hepatitis with a 12-month course of interferon alpha-2B. Results of a randomized controlled trial. Liver, 15, 45-52.
43. Gerberding, J. L. (1994). Incidence and prevalence of human immunodeficiency virus, hepatitis B virus, hepatitis C virus, and cytomegalovirus among health care personnel at risk for blood exposure: Final report from a longitudinal study. Journal of Infectious Diseases, 170, 1410-1417.
44. Gerlich, W. H., & Tomssen, R. (1999). Structure, replication, and laboratory diagnosis of hepatitis viruses. In J. Bircher, J. Behamou, N. McIntyre, M. Rizzetto, & J. Rodes (Eds.), Oxford textbook of clinical hepatology (pp. 828-870). Oxford, UK: Oxford University Press.
45. Germer, J. J., & Zein, N. N. (2001). Advances in the molecular diagnosis of hepatitis C and their clinical implications. Mayo Clinic Proceedings, 76, 911-920.
46. Ghany, M. G., Leissinger, C., Lagier, R., Sanchez-Pescador, R., & Lok, A. S. (1996). Effect of human immunodeficiency virus infection on hepatitis C virus infection in hemophiliacs. Digestive Diseases and Sciences, 41, 1265-1272.
47. Gold Standard Media. (2003). Clinical pharmacology. Retrieved from http://cp.gsm.com
48. Gotsman, I., & Muszkat, M. (2001). Glucose-6-phosphate dehydrogenase deficiency is associated with increased initial clinical severity of acute viral hepatitis A. Journal of Gastroenterology and Hepatology, 16, 1239-1243.
49. Greub, G., Ledergerber, B., Battegay, M., Grob, P., Perrin, L., Furrer, H., et al. (2000). Clinical progression, survival, and immune recovery during antiretroviral therapy in patients with HIV-1 and hepatitis C virus coinfection: The Swiss HIV Cohort Study [Comment]. Lancet, 356(9244), 1800-1805. [Erratum appears in Lancet (2001, May 12), 357(9267), 1536]
50. Gross, J. B., Jr. (1998). Clinician's guide to hepatitis C. Mayo Clinic Proceedings, 73, 355-360.
51. Hadziyannis, S. J. (1996). Viral hepatitis: Clinical features. In B. R. Bacon & A. M. Di Bisceglie (Eds.), Liver disease: Diagnosis and management (pp. 79-97). London: Churchill Livingstone.
52. Hadziyannis, S. J. (1999). The new 'hepatitis' virus G or GBV-C. In J. Bircher, N. Benhamou, N. McIntyre, M. Rizzetto, & J. Rodes (Eds.), Oxford textbook of clinical hepatology (pp. 926-931). Oxford, UK: Oxford University Press.
53. Hawker, F. (1993). The liver: Anatomy, physiology, and biochemistry. In The liver: Critical care management (pp. 3-25). London: W. B. Saunders.
54. Heathcote, E. J., Shiffman, M. L., Cooksley, W. G., Dusheiko, G. M., Lee, S. S., Balart, L., et al. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C and cirrhosis. New England Journal of Medicine, 343, 1673-1680.
55. Huether, S. E. (1998). Alterations of digestive function. In K. L. McCance & S. E. Huether (Eds.), Pathophysiology: The biologic basis for disease in adults and children (3rd ed., pp. 1322-1379). St. Louis: Mosby.
56. Kahn, J. (2002). Preventing hepatitis A and hepatitis B infections among men who have sex with men. Clinical Infectious Diseases, 35, 1382-1387.
57. Keiper, J., Brouwer, A., Knook, D. I., & van Berkel, T. J. C. (1994). Kupffer and sinusoidal endothelial cells. In I. M. Arias, J. L. Boyer, N. Fausto, W. B. Jakoby, D. A. Schacter, & D. A. Shafritz (Eds.), The liver: Biology & pathobiology (pp. 791-818). New York: Raven Press.
58. Klatskin, G., & Conn, H. O. (2003). The normal liver. In Histopathology of the liver (pp. 9-14). New York: Oxford University Press.
59. Koff, R. S. (2001). Risks associated with hepatitis A and hepatitis B in patients with hepatitis C. Journal of Clinical Gastroenterology, 33, 20-26.
60. Koff, R. S. (2003). Hepatitis A and E. In D. Zakim & T. D. Boyer (Eds.), Hepatology: A textbook of liver disease (pp. 939-958). Philadelphia: W. B. Saunders.
61. Komine, F., Yamaguchi, T., Moriyama, M., Segawa, T., Matsumura, H., Nakai, K., et al. (1999). A case of sexually transmitted acute hepatitis C: Confirmation by analysis of viral genome. Hepatology Research, 14, 84-91.
62. Kramer, L., & Bauer, E. (2002). Extracorporeal treatment in fulminant hepatic failure: Pathophysiologic considerations. International Journal of Artificial Organs, 25, 929-934.
63. Lafeuillade, A., Hittinger, G., & Chadapaud, S. (2001). Increased mitochondrial toxicity with ribavirin in HIV/HCV coinfection. Lancet, 357, 280-281.
64. Lau, D. T., Kleiner, D. E., Ghany, M. G., Park, Y., Schmid, P., & Hoofnagle, J. H. (1998). 10-Year follow-up after interferon-alpha therapy for chronic hepatitis C. Hepatology, 28, 1121-1127.
65. Lau, J. Y., Davis, G. L., Prescott, L. E., Maertens, G., Lindsay, K. L., Qian, K., et al. (1996). Distribution of hepatitis C virus genotypes determined by line probe assay in patients with chronic hepatitis C seen at tertiary referral centers in the United States. Hepatitis Interventional Therapy Group. Annals of Internal Medicine, 124, 868-876.
66. Lau, J. Y., King, R., Tibbs, C. J., Catterall, A. P., Smith, H. M., Portmann, B. C., et al. (1993). Loss of HbsAg with interferon-alpha therapy in chronic hepatitis D virus infection. Journal of Medical Virology, 39, 292-296.
67. Lauer, G. M., & Walker, B. D. (2001). Hepatitis C virus infection. New England Journal of Medicine, 345, 41-52.
68. Liang, T. J., Rehermann, B., Seeff, L. B., & Hoofnagle, J. H. (2000). Pathogenesis, natural history, treatment, and prevention of hepatitis C. Annals of Internal Medicine, 132, 296-305.
69. Littell, R. D. (1999). Hepatitis A vaccine. Primary Care Update Obstetrics/Gynecology, 6, 205-208.
70. Maddrey, W. C. (1999). Safety of combination interferon alfa-2b/ ribavirin therapy in chronic hepatitis C-relapsed and treatment-naive patients. Seminars in Liver Disease, 19(Suppl. 1), 67-75.
71. Madejon, A., Cotonat, T., Bartolome, J., Castillo, I., & Carreno, V. (1994). Treatment of chronic hepatitis D virus infection with low and high doses of interferon-alpha 2a: Utility of polymerase chain reaction in monitoring antiviral response. Hepatology, 19, 1331-1336.
72. Manns, M. P., McHutchison, J. G., Gordon, S. C., Rustgi, V. K., Shiffman, M., Reindollar, R., et al. (2001). Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: A randomised trial. Lancet, 358(9286), 958-965.
73. Mazzella, G., Accogli, E., Sottili, S., Festi, D., Orsini, M., Salzetta, A., et al. (1996). Alpha interferon treatment may prevent hepatocellular carcinoma in HCV-related liver cirrhosis. Journal of Hepatology, 24, 141-147.
74. Mazzella, G., Saracco, G., Festi, D., Rosina, F., Marchetto, S., Jaboli, F., et al. (1999). Long-term results with interferon therapyin chronic type B hepatitis: A prospective randomized trial. American Journal of Gastroenterology, 94, 2246-2250.
75. McCormick, D. B., & Munro, H. N. (1994). Liver in relation to water-soluble vitamins. In I. M. Arias, J. L. Boyer, N. Fausto, W. B. Jakoby, D. A. Schacter, & D. A. Shafritz (Eds.), The liver: Biology & pathobiology (pp. 563-583). New York: Raven Press.
76. McHutchison, J. G., Gordon, S. C., Schiff, E. R., Shiffman, M. L., Lee, W. M., Rustgi, V. K., et al. (1998). Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. New England Journal of Medicine, 339, 1485-1492.
77. Moriyama, M., Matsumura, H., Shimizu, T., Shioda, A., Kaneko, M., Saito, H., et al. (2000). Hepatitis G virus coinfection influences the liver histology of patients with chronic hepatitis C. Liver, 20, 397-404.
78. Myers, R. P., Gregor, J. C., & Marotta, P. J. (2000). The cost-effectiveness of hepatitis A vaccination in patients with chronic hepatitis C. Hepatology, 31, 834-839.
79. Nair, S., & Perrillo, R. P. (2003). Hepatitis B and D. In D. Zakim & T. D. Boyer (Eds.), Hepatology: A textbook of liver disease (pp. 959-1016). Philadelphia: W. B. Saunders.
80. National Institutes of Health Consensus Development Conference Panel. (1997). Management of Hepatitis C. Hepatology, 26, 2S-10S.
81. Niederau, C., Lange, S., Heintges, T., Erhardt, A., Buschkamp, M., Hurter, D., et al. (1998). Prognosis of chronic hepatitis C: Results of a large, prospective cohort study. Hepatology, 28(6), 1687-1695.
82. Nishiguchi, S., Kuroki, T., Nakatani, S., Morimoto, H., Takeda, T., Nakajima, S., et al. (1995). Randomised trial of effects of interferon-alpha on incidence of hepatocellular carcinoma in chronic active hepatitis C with cirrhosis. Lancet, 346, 1051-1055.
83. O'Donovan, D., Cooke, R. P., Joce, R., Eastbury, A., Waite, J., & Stene-Johansen, K. (2001). An outbreak of hepatitis A amongst injecting drug users. Epidemiology and Infection, 127, 469-473.
84. Ockenga, J., Tillmann, H. L., Trautwein, C., Stoll, M., Manns, M. P., & Schmidt, R. E. (1997). Hepatitis B and C in HIV-infected patients. Prevalence and prognostic value. Journal of Hepatology, 27, 18-24.
85. Okuda, M., Hino, K., Korenaga, M., Yamaguchi, Y., Katoh, Y., & Okita, K. (1999). Differences in hypervariable region 1 quasispecies of hepatitis C virus in human serum, peripheral blood mononuclear cells, and liver. Hepatology, 29, 217-222.
86. Oliveri, F., Colombatto, P., Derezini, M., Trere, D., Papotti, M., David, E., et al. (1993). Hepatocellular carcinoma: Pathogenic implications of the hepatitis delta virus. Progress in Clinical and Biological Research, 382, 170.
87. Osmond, D. H., Charlebois, E., Sheppard, H. W., Page, K., Winkelstein, W., Moss, A. R., et al. (1993). Comparison of risk factors for hepatitis C and hepatitis B virus infection in homosexual men. Journal of Infectious Diseases, 167, 66-71.
88. Painter, P., Krasnoff, J., Paul, S. M., & Ascher, N. L. (2001). Physical activity and health-related quality of life in liver transplant recipients. Liver Transplantation, 7, 213-219.
89. Pawlotsky, J. M., Bouvier-Alias, M., Hezode, C., Darthuy, F., Remire, J., & Dhumeaux, D. (2000). Standardization of hepatitis C virus RNA quantification. Hepatology, 32, 654-659.
90. Picchio, G. R., Nakatsuno, M., Boggiano, C., Sabbe, R., Corti, M., Daruich, J., et al. (1997). Hepatitis C (HCV) genotype and viral titer distribution among Argentinean hemophilic patients in the presence or absence of human immunodeficiency virus (HIV) coinfection. Journal of Medical Virology, 52, 219-225.
91. Poovorawan, Y., Chatchatee, P., & Chongsrisawat, V. (2002). Epidemiology and prophylaxis of viral hepatitis: A global perspective. Journal of Gastroenterology and Hepatology, 17, S155-S166.
92. Porth, C. M. (2002). Alterations in function of the hepatobiliary system and exocrine pancreas. In C. M. Porth (Ed.), Pathophysiology: Concepts of altered health states (pp. 859-888). Philadelphia: Lippincott Williams and Wilkins.
93. Poynard, T., Bedossa, P., & Opolon, P. (1997). Natural history of liver fibrosis progression in patients with chronic hepatitis C. The OBSVIRC, METAVIR, CLINIVIR, and DOSVIRC groups. Lancet, 349, 825-832.
94. Poynard, T., Marcellin, P., Lee, S. S., Niederau, C., Minuk, G. S., Ideo, G., et al. (1998). Randomised trial of interferon alpha2b plus ribavirin for 48 weeks or for 24 weeks versus interferon alpha2b plus placebo for 48 weeks for treatment of chronic infection with hepatitis C virus. International Hepatitis Interventional Therapy Group (IHIT). Lancet, 352, 1426-1432.
95. Randall, E. (1995). Alterations in hemostasis and blood coagulation. In L. C. Copstead (Ed.), Perspectives onpathophysiology (pp. 286-300). Philadelphia: W. B. Saunders.
96. Reingold, A. L., & Phares, C. R. (2001). Infectious diseases. In M. H. Merson, R. E. Black, & A. J. Mills (Eds.), International public health: Diseases, programs, systems, and policies (pp. 139-206). Gaithersburg, MD: Aspen.
97. Riley, T. R., III, & Bhatti, A. M. (2001). Preventive strategies in chronic liver disease: Part I. Alcohol, vaccines, toxic medications and supplements, diet and exercise. American Family Physician, 64, 1555-1560.
98. Robertson, B., Myers, G., Howard, C., Brettin, T., Bukh, J., Gaschen, B., et al. (1998). Classification, nomenclature, and database development for hepatitis C virus (HCV) and related viruses: Proposals for standardization. International Committee on Virus Taxonomy. Archives of Virology, 143, 2493-2503.
99. Rockstroh, J. K., Spengler, U., Sudhop, T., Ewig, S., Theisen, A., Hammerstein, U., et al. (1996). Immunosuppression may lead to progression of hepatitis C virus-associated liver disease in hemophiliacs coinfected with HIV. American Journal of Gastroenterology, 91, 2563-2568.
100. Rosina, F., Pintus, C., Meschievitz, C., & Rizzetto, M. (1991). A randomized controlled trial of a 12-month course of recombinant human interferon-alpha in chronic delta (type D) hepatitis: A multicenter Italian study. Hepatology, 13, 1052-1056.
101. Rossi, S. J., Volberding, P. A., & Wright, T. L. (2002). Does hepatitis C virus infection increase the risk of HIV disease progression? Journal of the American Medical Association, 288(2), 241-243.
102. Rubin, E., & Farber, J. L. (1999). The liver & biliary system. In Pathology (pp. 757-838). Philadelphia: Lippincott-Raven.
103. Rutschmann, O. T., Negro, F., Hirschel, B., Hadengue, A., Anwar, D., & Perrin, L. H. (1998). Impact of treatment with human immunodeficiency virus (HIV) protease inhibitors on hepatitis C viremia in patients coinfected with HIV. Journal of Infectious Diseases, 177(3), 783-785.
104. Sacher, R. A., & McPherson, R. A. (2000). Widmann's clinical interpretation of laboratory tests. Philadelphia: F. A. Davis.
105. Seifter, S., & England, S. (1994). Energy metabolism. In I. M. Arias, J. L. Boyer, N. Fausto, W. B. Jakoby, D. A. Schacter, & D. A. Shafritz (Eds.), The liver: Biology & pathophysiology (pp. 323-364). New York: Raven Press.
106. Serfaty, L., Aumaitre, H., Chazouilleres, O., Bonnand, A. M., Rosmorduc, O., Poupon, R. E., et al. (1998). Determinants of outcome of compensated hepatitis C virus-related cirrhosis. Hepatology, 27, 1435-1440.
107. Sherman, K. E., O'Brien, J., Gutierrez, A. G., Harrison, S., Urdea, M., Neuwald, P., et al. (1993). Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections. Journal of Clinical Microbiology, 31, 2679-2682.
108. Soto, B., Sanchez-Quijano, A., Rodrigo, L., del Olmo, J. A., Garcia-Bengoechea, M., Hernandez-Quero, J., et al. (1997). Human immunodeficiency virus infection modifies the natural history of chronic parenterally-acquired hepatitis C with an unusually rapid progression to cirrhosis. Journal of Hepatology, 26, 1-5.
109. Starace, F., Ammassari, A., Trotta, M. P., Murri, R., De Longis, P., Izzo, C., et al. (2002). Depression is a risk factor for suboptimal adherence to highly active antiretroviral therapy. Journal of Acquired Immune Deficiency Syndromes, 31(Suppl. 3), S136-S139.
110. Stolz, A. (2002). Liver physiology & metabolic function. In M. Feldman, L. S. Friedman, & M. H. Sleisenger (Eds.), Sleisenger & Fordtran's gastrointestinal & liver disease: Pathology/diagnosis/management (pp. 1202-1226). Philadelphia: W. B. Saunders.
111. Sulkowski, M. S., Moore, R. D., Mehta, S. H., Chaisson, R. E., & Thomas, D. L. (2002). Hepatitis C and progression of HIV disease [Comment]. Journal of the American Medical Association, 288(2), 199-206.
112. Talal, A. H., & Dieterich, D. T. (1999). Gastrointestinal and hepatic manifestations of HIV infection. In M. A. Sande & P. A. Volberding (Eds.), The medical management of AIDS (6th ed., pp. 195-216). Philadelphia: W. B. Saunders.
113. Telfer, P., Sabin, C., Devereux, H., Scott, F., Dusheiko, G., & Lee, C. (1994). The progression of HCV-associated liver disease in a cohort of haemophilic patients. British Journal of Haematology, 87, 555-561.
114. Thomas, D. L., Shih, J. W., Alter, H. J., Vlahov, D., Cohn, S., Hoover, D. R., et al. (1996). Effect of human immunodeficiency virus on hepatitis C virus infection among injecting drug users. Journal of Infectious Diseases, 174, 690-695.
115. Tine, F., Magrin, S., Craxi, A., & Pagliaro, L. (1991). Interferon for non-A, non-B chronic hepatitis. A meta-analysis of randomised clinical trials. Journal of Hepatology, 13, 192-199.
116. Valla, D. C., Chevallier, M., Marcellin, P., Payen, J. L., Trepo, C., Fonck, M., et al. (1999). Treatment of hepatitis C virus-related cirrhosis: A randomized, controlled trial of interferon alfa-2b versus no treatment. Hepatology, 29, 1870-1875.
117. Vento, S., Garofano, T., Renzini, C., Cainelli, F., Casali, F., Ghironzi, G., et al. (1998). Fulminant hepatitis associated with hepatitis A virus superinfection in patients with chronic hepatitis C. New England Journal of Medicine, 338, 286-290.
118. Veterans Administration. (2003). New HCV treatment guidelines from the veteran's administration. Retrieved from http://www. hcvadvocate.org/Oldsite/ Articles/VA%20Treatment% 20Recommendations.htm
119. Weissenborn, K. (1992). Recent developments in the pathophysiology and treatment of hepatic encephalopathy. Baillieres Clinical Gastroenterology, 6, 609-630.
120. Williams, I. (1999). Epidemiology of hepatitis C in the United States. American Journal of Medicine, 107, 2S-9S.
121. World Health Organization. (1998). The World Health Report 1998. Life in the 21st century: A vision for all. Report of the Director-General. Geneva, Switzerland: World Health Organization.
122. Wright, T. L., Hollander, H., Pu, X., Held, M. J., Lipson, P., Quan, S., et al. (1994). Hepatitis C in HIV-infected patients with and without AIDS: Prevalence and relationship to patient survival. Hepatology, 20(5), 1152-1155.
123. Yeo, A. E., Matsumoto, A., Hisada, M., Shih, J. W., Alter, H. J., & Goedert, J. J. (2000). Effect of hepatitis G virus infection on progression of HIV infection in patients with hemophilia. Multicenter Hemophilia Cohort Study. Annals of Internal Medicine, 132, 959-963.
124. Zane, H. D. (2003). Immunology: Theoretical and practical concepts in laboratory medicine. Philadelphia: W. B. Saunders.
125. Zein, N. N. (2000). Clinical significance of hepatitis C virus genotypes. Clinical Microbiology Reviews, 13, 223-235.
126. Zeuzem, S., Feinman, S. V., Rasenack, J., Heathcote, E. J., Lai, M. Y., Gane, E., et al. (2000). Peginterferon alfa-2a in patients with chronic hepatitis C. New England Journal of Medicine, 343, 1666-1672.
127. Ziegler, D. M. (1994). Detoxification: Oxidation and reduction. In I. M. Arias, J. L. Boyer, N. Fausto, W. B. Jakoby, D. A. Schacter, & D. A. Shafritz (Eds.), The liver: Biology & pathophysiology (pp. 415-427). New York: Raven Press.
128. Zignego, A. L., De Carli, M., Monti, M., Careccia, G., La Villa, G., Giannini, C., et al. (1995). Hepatitis C virus infection of mononuclear cells from peripheral blood and liver infiltrates in chronically infected patients. Journal of Medical Virology, 47, 58-64. 51S